目的 研究坤泰膠囊聯(lián)合米非司酮治療子宮肌瘤的臨床療效。方法 選取2018年6月-2020年6月北京市通州區(qū)婦幼保健院收治的106例子宮肌瘤患者為研究對象，將患者按照治療方法分為對照組和觀察組，每組各53例。對照組從月經(jīng)周期第1天開始服用米非司酮片，12.5 mg/次，1次/d；觀察組在對照組治療基礎(chǔ)上服用坤泰膠囊，4粒/次，3次/d。兩組連續(xù)治療3個月。觀察兩組患者的臨床療效，比較治療前后患者的子宮肌瘤及子宮體積、性激素水平、不良反應(yīng)發(fā)生情況以及復(fù)發(fā)率。結(jié)果 治療后，觀察組總有效率為98.11%，高于對照組的90.56%，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者子宮肌瘤及子宮積與治療前相比均有所縮小（P<0.05）；觀察組患者的子宮肌瘤及子宮積顯著小于對照組（P<0.05）。治療后，兩組促卵泡生成素、孕酮、雌二醇和促黃體生成素水平均顯著下降（P<0.05）；觀察組治療后激素水平明顯低于對照組（P<0.05）。治療過程中，觀察組不良反應(yīng)總發(fā)生率低于對照組（P<0.05）；治療后半年內(nèi)，觀察組子宮肌瘤復(fù)發(fā)率為1.89%，低于對照組的9.43%，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 坤泰膠囊聯(lián)合米非司酮聯(lián)合治療子宮肌瘤的療效顯著，有助于促進子宮肌瘤縮小，降低性激素水平，并能降低復(fù)發(fā)率，且用藥安全性高，值得推廣應(yīng)用。

Objective To study the clinical effect of Kuntai Capsules combined with mifepristone in treatment of uterine fibroids. Methods A total of 106 patients with uterine fibroids admitted to Tongzhou Maternal & Child Health Hospital of Beijing from June 2018 to June 2020 were selected as the research subjects, and the patients were divided into control group and observation group according to treatment methods, with 53 cases in each group. Patients in the control group were po administered with Mifepristone Tablets 12.5 mg/time, once daily from the first day of menstrual cycle. Patients in the observation group were po administered with Kuntai Capsules on the basis of control group, four grains/time, three times daily. Two groups were treated for three months. Clinical efficacy of two groups was observed, and uterine fibroids, uterine volume, sex hormone levels, the incidence of adverse reactions, and recurrence rate of patients before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 98.11%, which was higher than 90.56% of the control group, and the difference was statistically significant (P<0.05). After treatment, uterine fibroids and uterine volume in two groups were reduced compared with before treatment (P<0.05). The uterine fibroids and uterine volume in observation group were significantly lower than those in control group (P<0.05). After treatment, the levels of follicle stimulating hormone, progesterone, estradiol and luteinizing hormone in two groups were significantly decreased (P<0.05). The hormone level of observation group was significantly lower than control group after treatment (P<0.05). During treatment, the total incidence of ADR in observation group was lower than that in control group (P<0.05). Within half a year after treatment, the recurrence rate of uterine fibroids in the observation group was 1.89%, lower than 9.43% in the control group, and the difference was statistically significant (P<0.05). Conclusion Kuntai Capsules combined with mifepristone has a significant therapeutic effect on uterine fibroids, which is helpful to promote the reduction of uterine fibroids, reduce the level of sex hormones, and reduce the recurrence rate. Moreover, it has high safety and is worthy of popularization and application.

R984